Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Global pharmaceutical company Teva Pharmaceutical Industries Limited contributed to performance, outpacing the broader pharmaceutical sector. Second-quarter results showed...
— Neal Kaufman
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Teva Pharmaceutical Industries Limited
No other institutional pitches found for this ticker yet.
More institutional theses from Baron Health Care Fund
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
Thermo Fisher Scientific Inc. ($TMO) is the world's premier provider of life sciences tools, laboratory supplies, analytical instruments, and clinical trial services, representing 5.9% of fund assets. The investment manager...
Xenon Pharmaceuticals Inc. ($XENE) is a clinical-stage biopharmaceutical developer focused on novel ion channel therapies for neurological disorders. The manager adopted...